ReviewPathogens (Basel, Switzerland)2022
The Current Knowledge on
Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Proteomic antibacterial characterization of flavonoid xanthohumol and probiotic Clostridium butyricum on pathogenic Clostridioides difficile.Chinese medicine · 2026Article
- Diagnostic challenges and treatment approaches forFrontiers in microbiology · 2026Review
- Dynamic Microbiome Responses to Structurally Diverse Anthocyanin-Rich Foods in a Western Diet Context.Nutrients · 2025Article
- Association ofWorld journal of gastrointestinal surgery · 2025Article
- Risk factors for Clostridioides difficile infection among patients diagnosed with inflammatory intestinal and rheumatological diseases in the biologic era.BMC gastroenterology · 2025Article
- Advances in gut microbiota functions in inflammatory bowel disease: Dysbiosis, management, cytotoxicity assessment, and therapeutic perspectives.Computational and structural biotechnology journal · 2025Review
- The role of gut microbiota in the formation of IBD, a typical chronic intestinal inflammatory disease.Frontiers in microbiology · 2025Review
- Safety profile of TNF- alpha Inhibitors in pediatric patients: A post-marketing surveillance study based on the FAERS database.PloS one · 2025Article
- Management of inflammatory bowel disease in the emergency setting: the MIBODI international survey and evidence-based practices.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2024Article
- Article
- Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease.Pathogens (Basel, Switzerland) · 2023Review
- Article
- Review
- Review
- Review
- Article
- Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrentTherapeutic advances in gastroenterology · 2023Article
- Targeting pathophysiological changes using biomaterials-based drug delivery systems: A key to managing inflammatory bowel disease.Frontiers in pharmacology · 2022Review
- Transplant of microbiota from Crohn's disease patients to germ-free mice results in colitis.Gut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.